Genfit shares rise on NSI4 tech stage 1 study results

Genfit SA

19/11/2021 09:05

** Shares in biopharma group Genfit  GNFT.PA  rise 7.4%
after its NSI4 technology proved to be able to identify
"at-risk" non-alcoholic steatohepatitis (NASH) patients in a
stage 1 study  urn:newsml:reuters.com:*:nASN001WNQ
    ** The study by the Non-Invasive Biomarkers of Metabolic
Liver Disease (NIMBLE) initiative showed that the technology can
also diagnose neonatal abstinence syndrome at stage four or
higher and fibrosis at stage two or higher
    ** Genfit, down nearly 18% year to date, is heading for its
best day since the end of August

 (Reporting by Juliette Portala)
 ((juliette.portala@tr.com))